BG-102 is under clinical development by SL Bigen and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BG-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BG-102 overview
BG-102 is under development for the treatment of type 2 diabetes and obesity. The therapeutic candidate is a bispecific fusion protein.
SL Bigen overview
SL Bigen a research-based bio-genetic engineering company that develops and commercializes next-generation immunotherapies. SL Bigen develops stem cell lines designed to produce disease-specific therapeutic genes and also multi-engineered natural killer cell lines expressing fourth generation chimeric antigen receptors. The company’s manufacturing unit for the research and development of cell-based gene therapy is comprised of QC laboratory, process development room, and storage facility. SL Bigen offers its services through CAR-NK (chimeric antigen receptor-directed natural killer) and eMSC (expressing mesenchymal stem cells) programs. SL Bigen is headquartered in Incheon, South Korea.
For a complete picture of BG-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.